Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second phase 3 trial, in hot ...

Bavarian Nordic has won US Food and Drug Administration (FDA) approval for its chikungunya vaccine Vimkunya, becoming the ...

There are now two vaccines to protect against chikungunya approved for use in the US, with Bavarian Nordic Vimkunya becoming the first cleared for use in adolescents. The Danish biopharma company ...

The UK approval of VIMKUNYA marks the third approval of Bavarian Nordic’s chikungunya vaccine, which was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in ...

Bavarian Nordic’s chikungunya virus vaccine candidate has racked up a second phase 3 victory. Weeks after presenting positive data in seniors, the biotech has revealed pivotal results in younger ...

Bavarian Nordic's chikungunya vaccine application has been submitted for approval to Health Canada, with potential authorisation expected in the first half of 2026.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers. ... 2025– Bavarian Nordic A/S ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the ...

Bavarian Nordic A/S's BVNRY phase 3 chikungunya virus vaccine (CHIKV VLP (PXVX0317) clinical trial has hit its primary endpoint in healthy adults ≥65 years of age.. In the 22 days after ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers. On track for commercial launch in the U.S. in ...

Bavarian Nordic A/S's (OTC: BVNRY) phase 3 chikungunya virus vaccine (CHIKV VLP (PXVX0317) clinical trial has hit its primary endpoint in healthy adults ≥65 years of age. In the 22 days after ...